Related Experiment Video
Updated: Dec 18, 2025
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Novel benzimidazole derivatives: Synthesis, in vitro cytotoxicity, apoptosis and cell cycle studies
Harika Atmaca1, Süleyman İlhan1, Muhammet Burak Batır1
1Section of Molecular Biology, Department of Biology, Faculty of Science and Letters, Manisa Celal Bayar University, Muradiye, Manisa, Turkey.
Abstract:
The aim of the study was to synthesize a new series of benzimidazole derivatives and to investigate the underlying molecular mechanisms of the potential cell cycle inhibition and apoptotic effects against a panel of selected human cancer cell lines along with HEK-293 human embryonic kidney cells. MTT assay was used to evaluate cytotoxic effects. Muse™ Cell Analyzer was used to assess cell cycle progression. Annexin-V/PI staining assay was used for detecting apoptosis. All the synthesized compounds showed a significant cytotoxic effect against cancer cells with the IC50 values between 9.2 and 166.1 μg/mL. Among the tested derivatives, compound 5 showed significant cytotoxic activity against MCF-7, DU-145 and H69AR cancer cells with the IC50 values of 17.8 ± 0.24, 10.2 ± 1.4 and 49.9 ± 0.22 μg/mL respectively. The compounds 5 was also tested on HEK-293 human embryonic kidney cells and found to be safer with lesser cytotoxicity. The results revealed that compound 5 significantly increased cell population in the G2/M-phase which is modulated by a p53 independent mechanism. Compound 5 caused an increase in the percentage of late apoptotic cells in all tested cancer cells in a concentration-dependent manner. Among all synthesized derivatives, compound 5 the bromo-derivative, showed the highest cytotoxic potential, induced G2/M cell cycle arrest and apoptotic cell death in genotypically different human cancer cells. These results suggest that compound 5 might be a promising agent for cancer therapy and further structural modifications of benzimidazole derivatives may create promising anticancer agents.
Insights
A new benzimidazole derivative, compound 5, effectively inhibits cancer cell growth by inducing cell cycle arrest and apoptosis. This promising anticancer agent demonstrates significant cytotoxicity against various cancer types while showing safety in normal cells.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Benzimidazole derivatives are explored for their therapeutic potential.
- Understanding molecular mechanisms of novel anticancer agents is crucial.
Purpose of the Study:
- Synthesize novel benzimidazole derivatives.
- Investigate their cytotoxic and apoptotic effects on human cancer cells.
- Elucidate the molecular mechanisms of action, including cell cycle effects.
Main Methods:
- Cytotoxicity was evaluated using MTT assays.
- Cell cycle progression was analyzed with Muse™ Cell Analyzer.
- Apoptosis was detected via Annexin-V/PI staining.
Main Results:
- All synthesized compounds exhibited significant cytotoxicity (IC50: 9.2-166.1 μg/mL).
- Compound 5 showed potent activity against MCF-7, DU-145, and H69AR cells (IC50: 17.8, 10.2, 49.9 μg/mL, respectively).
- Compound 5 induced G2/M cell cycle arrest via a p53-independent pathway and increased late apoptotic cells.
Conclusions:
- Compound 5, a bromo-derivative, is a potent anticancer agent inducing cell cycle arrest and apoptosis.
- Compound 5 demonstrates selective toxicity towards cancer cells over normal HEK-293 cells.
- Further development of benzimidazole derivatives holds promise for novel cancer therapies.
